← All themes
Theme

Medical Devices

Every analyzed stock in Medical Devices — 253 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Medical Devices risk
Near-term vs. long-term risk for this theme
⚡ Right now ?Near-term risk over roughly the next 3 months. Blends live market conditions (volatility, how far the S&P is from its highs, credit spreads, the yield curve, sentiment), how stretched valuations are, and what the smart money is doing. Higher = greater odds of a pullback. · next 0–3 months
43 /100 Elevated ▲ +1 slight
Long-term risk ?Long-term / structural risk — the market's underlying tide. Where valuations sit versus 145 years of history (Shiller CAPE) plus multi-year trends. A high reading means weak long-run return prospects even if the market feels calm right now. · structural · vs 145yr history
66 /100 High ▲ +5 mild
▲ / ▼ = change vs ~7 days ago — red = risk rising, green = falling.
Inside the "right now" score — a 45 / 30 / 25 blend · 138 stocks valued
Conditions · 45% ?The live market weather: VIX (expected volatility), how far the S&P 500 is below its 52-week high, high-yield credit spreads, the 10-year vs 2-year yield curve, and the Fear & Greed index. Market-wide indices, not per-stock.
33 Moderate
Valuation · 30% ?How expensive stocks are versus our intrinsic-value models: the median price-to-value ratio and the share of stocks trading above what we think they are worth, across 138 stocks.
51 Elevated
Smart money · 25% ?What informed money is doing: short-selling activity plus corporate insiders buying or selling their own stock. Broken out below.
45 Elevated
Smart money — the three inputs
Short-selling ?Share of ALL US trading volume that is short sales (FINRA, ~12,000 symbols, market-wide). It normally sits near 45–50%, so readings above ~50% lean bearish and read as higher risk. Weighted 40% of Smart money.
49.5%
Elevated
Buyers' strike ?Share of the sampled companies whose insiders bought NONE of their own stock on the open market in the last 12 months. The higher this runs, the more bearish (nobody's buying the dip in their own shares). Weighted 35%.
55%
Elevated
Net insider selling ?Share of the sampled companies whose insiders were net DISCRETIONARY sellers over 12 months (excludes scheduled 10b5-1 plans, which carry little signal). Around half is normal; well above that is bearish. Weighted 25%.
31%
Moderate
Black number = the raw figure; coloured bar & word = how it reads as risk. Insider inputs from 213 stocks (full universe); short-selling is market-wide.
Long-term risk: the long-term read runs high mainly because valuations sit near a historic extreme (Shiller CAPE) — a structural backdrop, not about this week.
Scale (0–100): 0–20 Low · 20–40 Moderate · 40–60 Elevated · 60–80 High · 80–100 Extreme. "Right now" reads today's conditions; the "long-term" score is anchored to ~145 years of valuation history.
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
This week in Medical Devices
Medical Devices — Sep 7 – Sep 11, 2026 (Wk 37): Medical Device Stocks See Elevated Risk Amid Earnings and Valuation Scrutiny →
The medical devices sector experienced an increase in its risk score this week, coinciding with several companies reporting earnings and investors evaluating valuations. While some firms showed profit growth, others faced scrutiny regarding their stock prices…
LNSR
LENSAR, Inc.
Deeply undervalued
Healthcare Risk 28 · Moderate
Price$7.60
Model IV$10.20
P/IV0.57
Discount 25% Return to IV: +34.2%
Market implies -12.1%/yr vs model +15.0% · below model
LPTH
LIGHTPATH TECHNOLOGIES INC
Valuation N/A
Technology Risk 36 · Moderate
Price$9.20
Model IV—
P/IV—
Market implies +65.6%/yr vs model +2.0% · above model
LUCD
Lucid Diagnostics Inc.
Deeply overvalued
Healthcare Risk 60 · High
Price$0.78
Model IV$0.30
P/IV3.46
Premium +163% Return to IV: -62.0%
Market implies +9.8%/yr vs model +50.0% · below model
LUNG
Pulmonx Corp
Deeply overvalued
Healthcare Risk 53 · Elevated
Price$1.85
Model IV$1.11
P/IV1.49
Premium +67% Return to IV: -40.3%
Market implies +10.3%/yr vs model +16.9% · below model
MASI
MASIMO CORP
Deeply overvalued
Healthcare Risk 52 · Elevated
Price$179.95
Model IV$57.69
P/IV3.09
Premium +212% Return to IV: -67.9%
Market implies +16.8%/yr vs model +2.6% · above model
MBAI
Check-Cap Ltd
Valuation N/A
Healthcare Risk 37 · Moderate
Price$6.49
Model IV—
P/IV—
Limited data — see page
MBOT
Microbot Medical Inc.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.45
Model IV—
P/IV—
Limited data — see page
MDAI
Spectral AI, Inc.
Deeply overvalued
Healthcare Risk 68 · High
Price$1.60
Model IV$0.82
P/IV2.54
Premium +96% Return to IV: -49.0%
Market implies +6.4%/yr vs model +15.0% · below model
MDAIW
Spectral AI, Inc.
Fairly valued
Healthcare Risk 58 · Elevated
Price$0.53
Model IV$0.51
P/IV1.03
Premium +3% Return to IV: -2.9%
Market implies -2.3%/yr vs model +15.0% · below model
MDLN
Medline Inc.
Undervalued
Healthcare Risk 37 · Moderate
Price$32.53
Model IV$47.28
P/IV0.77
Discount 31% Return to IV: +45.3%
Market implies +3.5%/yr vs model +10.4% · below model
MDT
Medtronic plc
Deeply undervalued
Healthcare Risk 26 · Moderate
Price$90.96
Model IV$108.65
P/IV0.68
Discount 16% Return to IV: +19.4%
Market implies +2.9%/yr vs model +6.1% · below model
MDXG
MIMEDX GROUP, INC.
Deeply undervalued
Healthcare Risk 35 · Moderate
Price$4.72
Model IV$9.10
P/IV0.40
Discount 48% Return to IV: +92.7%
Market implies +0.9%/yr vs model +13.3% · below model
MEDP
Medpace Holdings, Inc.
Undervalued
Industrials Risk 33 · Moderate
Price$595.41
Model IV$767.78
P/IV0.58
Discount 22% Return to IV: +28.9%
Market implies +12.7%/yr vs model +21.2% · below model
MEI
METHODE ELECTRONICS INC
Deeply undervalued
Technology Risk 38 · Moderate
Price$13.62
Model IV$23.97
P/IV0.48
Discount 43% Return to IV: +76.0%
Market implies -5.1%/yr vs model +2.0% · below model
MLSS
MILESTONE SCIENTIFIC INC.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$0.44
Model IV—
P/IV—
Market implies +28.1%/yr vs model +2.0% · above model
MMED
MiniMed Group, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$22.50
Model IV—
P/IV—
Limited data — see page
MMSI
MERIT MEDICAL SYSTEMS INC
Undervalued
Healthcare Risk 29 · Moderate
Price$86.36
Model IV$80.83
P/IV0.78
Premium +7% Return to IV: -6.4%
Market implies +8.5%/yr vs model +9.3% · in line
MOBI
Mobia Medical, Inc.
Valuation N/A
Healthcare Risk 54 · Elevated
Price$10.77
Model IV—
P/IV—
Limited data — see page
MODD
Modular Medical, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$2.41
Model IV—
P/IV—
Limited data — see page
MSA
MSA Safety Inc
Overvalued
Healthcare Risk 47 · Elevated
Price$178.79
Model IV$154.44
P/IV1.07
Premium +16% Return to IV: -13.6%
Market implies +8.9%/yr vs model +8.3% · in line
MTLS
MATERIALISE NV
Valuation N/A
Technology Risk 41 · Elevated
Price$7.66
Model IV—
P/IV—
Limited data — see page
MYO
MYOMO, INC.
Overvalued
Healthcare Risk 58 · Elevated
Price$1.24
Model IV$0.97
P/IV1.59
Premium +28% Return to IV: -21.9%
Market implies +1.2%/yr vs model +15.0% · below model
NDRA
ENDRA Life Sciences Inc.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$5.62
Model IV—
P/IV—
Limited data — see page
NEON
Neonode Inc.
Valuation N/A
Technology Risk 33 · Moderate
Price$0.83
Model IV—
P/IV—
Market implies +26.8%/yr vs model +2.0% · above model
NEPH
NEPHROS INC
Fairly valued
Healthcare Risk 37 · Moderate
Price$4.06
Model IV$3.98
P/IV0.92
Premium +2% Return to IV: -2.1%
Market implies +7.8%/yr vs model +14.5% · below model
NMTC
NEUROONE MEDICAL TECHNOLOGIES Corp
Fairly valued
Healthcare Risk 50 · Elevated
Price$1.56
Model IV$1.66
P/IV2.14
Discount 6% Return to IV: +6.3%
Market implies -7.9%/yr vs model +50.0% · below model
NNDM
Nano Dimension Ltd.
Valuation N/A
Technology Risk 33 · Moderate
Price$1.53
Model IV—
P/IV—
Market implies -50.0%/yr vs model +15.0% · below model
NNNN
Anbio Biotechnology
Valuation N/A
Healthcare Risk 53 · Elevated
Price$6.54
Model IV—
P/IV—
Market implies +34.1%/yr vs model +2.0% · above model
NNOX
Nano-X Imaging Ltd.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$0.70
Model IV—
P/IV—
Limited data — see page
NOTV
Inotiv, Inc.
Valuation N/A
Industrials Risk 54 · Elevated
Price$0.01
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
NPCE
NeuroPace Inc
Deeply overvalued
Healthcare Risk 72 · High
Price$14.04
Model IV$4.76
P/IV3.47
Premium +195% Return to IV: -66.1%
Market implies +14.4%/yr vs model +22.0% · below model
NRXS
Neuraxis, INC
Valuation N/A
Healthcare Risk 37 · Moderate
Price$5.74
Model IV—
P/IV—
Market implies +32.9%/yr vs model +10.0% · above model
NSPR
InspireMD, Inc.
Deeply overvalued
Healthcare Risk 51 · Elevated
Price$0.79
Model IV$0.21
P/IV4.38
Premium +276% Return to IV: -73.4%
Market implies +11.5%/yr vs model +18.9% · below model
NSYS
NORTECH SYSTEMS INC
Deeply overvalued
Technology Risk 57 · Elevated
Price$11.19
Model IV$7.71
P/IV1.94
Premium +45% Return to IV: -31.1%
Market implies +4.7%/yr vs model +4.1% · in line
NTRB
NutriBand Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$6.96
Model IV—
P/IV—
Market implies +42.4%/yr vs model +14.6% · above model
NTRBW
NutriBand Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$0.60
Model IV—
P/IV—
Limited data — see page
NUWE
Nuwellis, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.77
Model IV—
P/IV—
Market implies -36.3%/yr vs model +2.0% · below model
NVCR
NovoCure Ltd
Valuation N/A
Healthcare Risk 50 · Elevated
Price$16.22
Model IV—
P/IV—
Market implies +35.6%/yr vs model +5.2% · above model
NVEC
NVE CORP /NEW/
Deeply overvalued
Technology Risk 62 · High
Price$100.51
Model IV$31.59
P/IV3.10
Premium +218% Return to IV: -68.6%
Market implies +18.6%/yr vs model +3.4% · above model
NVNO
enVVeno Medical Corp
Valuation N/A
Healthcare Risk 43 · Elevated
Price$10.49
Model IV—
P/IV—
Limited data — see page
NVST
Envista Holdings Corp
Deeply overvalued
Healthcare Risk 59 · Elevated
Price$25.79
Model IV$17.40
P/IV1.35
Premium +48% Return to IV: -32.5%
Market implies +10.4%/yr vs model +5.6% · above model
NXGL
NEXGEL, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.28
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
NXL
Nexalin Technology, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$4.82
Model IV—
P/IV—
Market implies +111.9%/yr vs model +20.3% · above model
NYXH
Nyxoah SA
Valuation N/A
Healthcare Risk 51 · Elevated
Price$1.60
Model IV—
P/IV—
Limited data — see page
OACC
Oaktree Acquisition Corp. III Life Sciences
Valuation N/A
Financial Services
Price$10.77
Model IV—
P/IV—
Limited data — see page
OBIO
Orchestra BioMed Holdings, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$6.12
Model IV—
P/IV—
Market implies +44.1%/yr vs model +15.0% · above model
OFIX
Orthofix Medical Inc.
Deeply undervalued
Healthcare Risk 32 · Moderate
Price$8.93
Model IV$52.46
P/IV0.18
Discount 83% Return to IV: +487.5%
Market implies -34.7%/yr vs model +15.4% · below model
OM
Outset Medical, Inc.
Valuation N/A
Healthcare Risk 48 · Elevated
Price$3.21
Model IV—
P/IV—
Limited data — see page
ONMD
OneMedNet Corp
Valuation N/A
Industrials Risk 45 · Elevated
Price$0.65
Model IV—
P/IV—
Market implies +63.7%/yr vs model +15.0% · above model
OSRH
OSR Holdings, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.20
Model IV—
P/IV—
Market implies +10.9%/yr vs model +15.0% · below model
OSUR
ORASURE TECHNOLOGIES INC
Valuation N/A
Healthcare Risk 41 · Elevated
Price$3.25
Model IV—
P/IV—
Market implies +17.8%/yr vs model +2.0% · above model
PASW
Ping An Biomedical Co., Ltd.
Fairly valued
Consumer Cyclical Risk 50 · Elevated
Price$0.13
Model IV$0.13
P/IV1.23
Premium +4% Return to IV: -3.9%
Market implies -6.3%/yr vs model +15.0% · below model
PAVM
PAVmed Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$4.18
Model IV—
P/IV—
Market implies +91.1%/yr vs model +2.0% · above model
PCSC
Perceptive Capital Solutions Corp
Valuation N/A
Healthcare Risk 39 · Moderate
Price$11.95
Model IV—
P/IV—
Limited data — see page
PDEX
PRO DEX INC
Deeply overvalued
Healthcare Risk 67 · High
Price$62.81
Model IV$44.41
P/IV1.46
Premium +41% Return to IV: -29.3%
Market implies -0.6%/yr vs model +15.0% · below model
PEN
Penumbra Inc
Deeply overvalued
Healthcare Risk 58 · Elevated
Price$317.73
Model IV$221.14
P/IV1.44
Premium +44% Return to IV: -30.4%
Market implies -4.4%/yr vs model +17.1% · below model
PFSA
Profusa, Inc.
Valuation N/A
Healthcare Risk 28 · Moderate
Price$2.43
Model IV—
P/IV—
Market implies +33.5%/yr vs model +15.0% · above model
PHG
KONINKLIJKE PHILIPS NV
Valuation N/A
Healthcare Risk 34 · Moderate
Price$24.59
Model IV—
P/IV—
Limited data — see page
PLRZ
Polyrizon Ltd.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$11.03
Model IV—
P/IV—
Limited data — see page
PLSE
PULSE BIOSCIENCES, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$53.11
Model IV—
P/IV—
Market implies +150.0%/yr vs model +2.0% · above model